Tripep AB (publ.) Interim Report, January - March 2005

· The loss after tax for the first quarter 2005 was SEK -5.2 million (-6.8 m). · Research and development costs were SEK 2.1 million (4.0 m) for the first quarter 2005, with an additional SEK 2.4 million capitalised. · The company recorded no net sales in the period. · First-quarter 2005 earnings per share were SEK -0.35 (-0.54). · All the documentation necessary for approval of the company’s first phase I/II clinical trial on its new anti-HIV drug alphaHGA was filed with the Thai authorities in February. · Another active analogue of alphaHGA was identified. · Tripep was granted its first US patent for ChronVac C®. · Tripep acquired the commercial rights to a test model for hepatitis C. For more information, please contact Jan Nilsson, Chief Executive Officer Tel: +46 (0)8 449 84 82, mobile: +46 (0)70 466 31 63 e-mail: Anders Vahlne, Head of Research Tel: +46 (0)8 5858 1313, mobile: +46 (0)70 928 05 28 e-mail:

About Us

ChronTech has developed and further develops a patent pending new type of injection needle for a more effective uptake of genetic vaccines (IVIN) and vaccine and therapy for hepatitis D. ChronTech also have part ownership in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium Nordic AB is Certified Adviser for ChronTech. For more information, please visit:

Documents & Links